IM188

IM188 is a preclinical small‑molecule immuno‑oncology agent from ImmunoMet Therapeutics that targets metabolic pathways in immune suppressor cells to enhance antitumor immunity. It belongs to the biguanide/OXPHOS‑inhibitor chemotype, similar to the company’s lead compound IM156, and is being developed for use in combination with checkpoint inhibitors such as anti‑PD‑1 antibodies, with preclinical data showing tumor regression in renal cancer models and activity across tumor types. Positioned as part of a broader cancer metabolism pipeline originating from Korean pharma Hanall Biopharma, IM188 aims to reprogram the tumor microenvironment and improve responses to existing immunotherapies.